论文部分内容阅读
用试管法和仪器法研究了蝰蛇毒磷脂时间（Russellvipervenumcoagulationtest,RVVCT）与血浆低分子肝素（lowmolecularweightheparin,LMWH）含量之间的关系。采用的实验条件为：蝰蛇毒100μl；脑磷脂（1：1000稀释）10μl；氯化钙（0．025mol／L）10μl；37℃水浴时间（仪器法为直接温浴时间）1．5min。上述条件下，血浆LMWH含量与凝固时间成良好的线性关系（直线回归γ＝0．96～0．99），批内变异系数0．6％～1．9％，批间变异系数1．7％～2．6％。尚建立了对倍稀释血浆LMWH的检测方法，扩大了检测范围，低分子肝素的最高检测限为2．0AXaIU／ml。使用上述方法对接受血液透析的患者和不稳定性心绞痛患者进行了血药浓度的观察。发现一次静脉注射低分子肝素100AXaIU／kg即能满足血透的抗凝要求。皮下给药每日一次150AXaIU／kg，三次可达到稳态血药浓度，长期给药时可固定剂量，基本不需调节剂量给药。
The relationship between the content of plasma low molecular weight heparin and low molecular weight heparin (RVWCT) was studied by test tube method and instrumental method. The experimental conditions were as follows: viper venom 100μl; brain phospholipid (1: 1000 dilution) 10μl; calcium chloride (0.025mol / L) 10μl; 37 ℃ water bath time (instrument method for direct warm bath time) 1.5min. Under the above conditions, the plasma LMWH content has a good linear relationship with the coagulation time (linear regression γ = 0.96 ~ 0.99), the intra-assay CV of 0.6% ~ 1.9% and the intra-assay CV of 1.7 % ~ 2.6%. We have also established a double dilution of plasma LMWH detection method to expand the detection range, the highest detection limit of low molecular weight heparin 2.0AXaIU / ml. Blood concentration was observed in patients undergoing hemodialysis and in patients with unstable angina using the methods described above. Found that a low-molecular-weight heparin intravenous injection of 100AXaIU / kg that can meet the hemodialysis anticoagulation requirements. Subcutaneous administration of 150AXaIU / kg once daily, three times to reach steady-state plasma concentration, long-term administration can be fixed dose, the basic dose without dose adjustment.